Jun 08, 2022 7:00 am EDT Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022
Jun 06, 2022 4:47 pm EDT Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022
May 23, 2022 4:05 pm EDT Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th
May 04, 2022 8:00 am EDT Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th
Feb 09, 2022 8:00 am EST Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Feb 04, 2022 7:00 am EST Immunovant Reports Financial Results for the Quarter Ended December 31, 2021